Results 171 to 180 of about 12,381 (205)

Adaptive immunotherapeutic paradigms in diffuse midline glioma: integrating epigenetic reprogramming, neuron-glioma interactions, and tumor microenvironment modulation. [PDF]

J Neurooncol
Liu J, Ha JH, Abikenari M, Sjoholm MA, Annagiri S, Ravi K, Bergsneider BH, Verma R, Theodros D, Medikonda R, Li G, Prolo LM, Monje M, Lim M.   +13 more
europepmc   +1 more source

Pathogen-specific Actinium-225 and Lutetium-177 labeled antibodies, as well as unbound radionuclide treatment show antimicrobial potential on a biofilm-associated implant infection - initial in vivo experience

Nurmohamed FRH, Allen KJ, Malo ME, Frank C, Duijvenbode JFFHv, Wildt Bvd, Poot AJ, Lam MGEH, Strijp JAG, Nikkels PG, Vogely HC, Weinans H, Dadachova E, Wal BCvd.   +13 more
europepmc   +1 more source

Comprehensive Analysis of 177Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination Schemes

Patzke S, Cascione L, Melhus KB, Munz N, Arribas AJ, Gaudio E, Generalov R, Repetto-Llamazares AH, Dahle J, Bertoni F.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Experimental radioimmunotherapy

Medical Physics, 1993
Radiolabeled monoclonal antibodies have been used for radioimmunotherapy studies with human tumor spheroids and murine and human tumor xenografts in experimental animals. This paper reviews the work that has been performed in these models with different types of cancer, and highlights those papers that have presented dosimetry estimates and attempts to
D J, Buchsbaum, V K, Langmuir, B W, Wessels   +2 more
openaire   +2 more sources

Experimental radioimmunotherapy

Seminars in Radiation Oncology, 2000
Experimental radioimmunotherapy (RIT) studies in animal models have contributed significantly to the design of clinical RIT protocols, although the results have not always been directly translated. Reviewed in this article are current areas of active research in experimental RIT to increase the therapeutic ratio that are likely to have a significant ...
openaire   +2 more sources

Radioimmunodetection and Radioimmunotherapy

Cancer Investigation, 1984
The development of monoclonal antibodies that recognize tumor-associated antigens has led to significantly greater practical possibilities for producing highly specific radiolabeled antibodies for diagnosis and therapy of human tumors. A number of problems remain before this technique will be ready for routine clinical application however.
S M, Larson, J A, Carrasquillo, J C, Reynolds   +2 more
openaire   +2 more sources

Anti-HER2 Radioimmunotherapy

Breast Disease, 2000
HER2/neu is a receptor protein whose overexpression strongly correlates with poor prognosis in breast carcinomas. It is used increasingly as a therapeutic target for breast carcinomas in clinical human trials. In particular, monoclonal antibodies (mAbs) that target HER2/neu have been investigated for therapeutic applications.
M W, Brechbiel, T A, Waldmann
openaire   +2 more sources

Radioimmunotherapy of brain tumor

Neurological Research, 2006
Despite years of intensive research, the prognosis of high-grade gliomas (HGG) remains poor, as these tumors are highly resistant to currently available therapies. Therefore, there is a need for the development of new therapeutic strategies, such as the use of monoclonal antibodies (MoAbs) in association with radioisotopes, in order to achieve better ...
Giovanni, Paganelli, Mirco, Bartolomei, Chiara, Grana, Mahila, Ferrari, Paola, Rocca, Marco, Chinol   +5 more
openaire   +2 more sources

Abscopal effect in radioimmunotherapy

International Immunopharmacology, 2020
Abscopal effect is an interesting phenomenon in radiobiology that causes activation of immune system against cancer cells. Traditionally, this phenomenon was known as a suppressor of non-irradiated tumors or metastasis. However, it can be used as a stimulator of the immune system against primary tumor during radiotherapy.
Milad, Ashrafizadeh, Bagher, Farhood, Ahmed, Eleojo Musa, Shahram, Taeb, Abolhassan, Rezaeyan, Masoud, Najafi   +5 more
openaire   +2 more sources

Fundamentals of radioimmunotherapy

International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1991
Design of a radioimmunotherapy trial is a complex process. This involves antibody selection, choice of radioisotope, and labeling method. Observation of the behavior of the new radiopharmaceutical involves determination of normal organ and tumor uptake, as well as residence time.
openaire   +2 more sources